Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Raw Materials: 2023-2025

Historic Raw Materials for Krystal Biotech (KRYS) over the last 2 years, with Sep 2025 value amounting to $14.6 million.

  • Krystal Biotech's Raw Materials rose 62.10% to $14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year increase of 62.10%. This contributed to the annual value of $13.6 million for FY2024, which is 332.44% up from last year.
  • Per Krystal Biotech's latest filing, its Raw Materials stood at $14.6 million for Q3 2025, which was up 3.59% from $14.1 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Raw Materials registered a high of $15.1 million during Q1 2025, and its lowest value of $3.2 million during Q4 2023.
  • Over the past 3 years, Krystal Biotech's median Raw Materials value was $11.3 million (recorded in 2024), while the average stood at $9.9 million.
  • Data for Krystal Biotech's Raw Materials shows a peak YoY surged of 332.44% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Krystal Biotech's Raw Materials stood at $3.2 million in 2023, then skyrocketed by 332.44% to $13.6 million in 2024, then skyrocketed by 62.10% to $14.6 million in 2025.
  • Its Raw Materials was $14.6 million in Q3 2025, compared to $14.1 million in Q2 2025 and $15.1 million in Q1 2025.